Pharmaceutical formulation and its use

US6630162B1 · kind B1 · utility

Assignee

• Pharmacia AB · SE

Inventors

• Lisbeth Nilvebrant · Bromma, SE
• Bengt Hallén · Sollentuna, SE
• Birgitta Olsson · Stenhamra, SE
• Jan Strömbom · Uppsala, SE
• Torkek Gren · Kalamazoo, US
• Anders Ringberg · Stockholm, SE
• Martin Wikberg · Lindome, SE

Key dates

• Filing date: Nov 9, 2000
• Grant date: Oct 7, 2003
• Expiry date: Nov 9, 2020

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K9/5047
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to a pharmaceutical formulation containing tolterodine or a tolterodine-related compound, or a pharmacologically acceptable salt thereof, as active ingredient, in which the formulation exhibits a controlled in vitro release of the active ingredient in phosphate buffer at pH 6.8 of not less than about 80% after 18 hours, and after oral administration to a patient is capable of maintaining a substantially constant serum level of the active moiety or moieties for 24 hours. The invention also relates to the use of the pharmaceutical formulation for treating overactive bladder and gastrointestinal disorders.